Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading ALIM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.31%72.131.0%$655.07m
AMGNAmgen Inc.
0.63%155.770.8%$509.15m
CELGCelgene Corporation
0.24%115.221.0%$465.18m
ARIAARIAD Pharmaceuticals, Inc.
0.23%23.7016.4%$416.43m
BIIBBiogen Inc.
0.21%283.611.0%$405.76m
ALXNAlexion Pharmaceuticals, Inc.
0.42%135.872.5%$385.05m
REGNRegeneron Pharmaceuticals, Inc.
-0.08%362.952.5%$365.07m
ILMNIllumina, Inc.
0.47%161.233.8%$225.12m
CLVSClovis Oncology, Inc.
0.64%56.6217.9%$166.73m
VRTXVertex Pharmaceuticals Incorporated
1.19%82.522.1%$152.50m
INCYIncyte Corporation
1.28%115.092.2%$149.42m
SRPTSarepta Therapeutics, Inc.
-0.42%35.9816.8%$110.90m
ACADACADIA Pharmaceuticals Inc.
3.06%32.3118.3%$110.16m
IONSIonis Pharmaceuticals, Inc.
1.12%47.148.9%$110.11m
TSROTESARO, Inc.
-1.32%149.2615.0%$109.40m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. It focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by C. Daniel Myers and David R. Holland and is headquartered in Alpharetta, GA.